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Equine Epidermis:
A Source of Epithelial-Like Stem/Progenitor Cells with
In Vitro and In Vivo Regenerative Capacities
Sarah Y. Broeckx,1,2 Sofie Maes,3,* Tiziana Martinello,4 De´sire´e Aerts,5 Koen Chiers,6 Tom Marie¨n,5
Marco Patruno,4 Alfredo Franco-Obrego´n,7,8 and Jan H. Spaas1,2
Besides the presence of somatic stem cells in hair follicles and dermis, the epidermis also contains a sub-
population of stem cells, reflecting its high regenerative capacity. However, only limited information con-
cerning epidermis-derived epithelial-like stem/progenitor cells (EpSCs) is available to date. Nonetheless, this
stem cell type could prove itself useful in skin reconstitution after injury. After harvesting from equine
epidermis, the purified cells were characterized as EpSCs by means of positive expression for CD29, CD44,
CD49f, CD90, Casein Kinase 2b, p63, and Ki67, low expression for cytokeratin (CK)14 and negative ex-
pression for CD105, CK18, Wide CK, and Pan CK. Furthermore, their self-renewal capacity was assessed in
adhesion as well as in suspension. Moreover, the isolated cells were differentiated toward keratinocytes and
adipocytes. To assess the regenerative capacities of EpSCs, six full-thickness skin wounds were made: three
were treated with EpSCs and platelet-rich-plasma (EpSC/PRP-treated), while the remaining three were ad-
ministered carrier fluid alone (PRP-treated). The dermis of EpSC/PRP-treated wounds was significantly thinner
and exhibited more restricted granulation tissue than did the PRP-treated wounds. The EpSC/PRP-treated
wounds also exhibited increases in EpSCs, vascularization, elastin content, and follicle-like structures. In
addition, combining EpSCs with a PRP treatment enhanced tissue repair after clinical application.
Introduction
In recent years, different classes of stem cells havebeen investigated for their ability to regenerate organs and
tissues after injury. Unlike embryonic stem cells, somatic
stem cells have a lower risk of teratogenesis and graft re-
jection. Consequently, the isolation and characterization of
stem cells from different adult tissues such as bone marrow
[1–3], adipose tissue [2], peripheral blood [4,5], or umbilical
cord (blood) [6,7] have been investigated. However, given
that the yield of stem cells from these tissues is low, purifi-
cation efficiency is critical and often limiting. On the other
hand, ongoing regeneration of the skin is achieved through
somatic stem cell differentiation within the epidermis and the
hair follicle. The skin may, hence, serve as an excellent
source of epithelial-like stem/progenitor cells (EpSCs) [8,9].
Accordingly, it has been proposed that EpSCs might be
useful in the treatment of several diseases, such as burn
wounds, chronic wounds, and ulcers [10]. In addition, ecto-
dermal dysplasias, monilethrix, Netherton syndrome,
Menkes disease, hereditary epidermolysis bullosa, and alo-
pecias may also benefit from the use of EpSCs [10].
Currently, epidermal-like stem cells have been obtained
by either dedifferentiating adult epidermal cells [11] or in-
ducing pluripotent stem cells [12]. The isolation of skin-
derived precursor cells with neurogenic properties has been
previously reported from human dermis [13–15] and hair
follicles [16] as have the isolation and partial purification of
adult multipotent stem cells from human and murine epi-
dermis [17,18]. For instance, Fujimori et al. reported the
isolation of human epidermal stem/progenitor cells by
means of gravity-assisted cell sorting [17]. However, the
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practice of selecting for stem cells based on size (diameter)
is problematic given that there exists a significant proportion
of somatic cells with equally small diameters, ultimately
resulting in a heterogeneous yield of cell types. On the other
hand, Nowak and Fuchs utilized fluorescence-activated cell
sorting (FACS) to isolate epidermal stem cells from mice
[18]. However, due to the lack of EpSC-specific markers,
cell sorting with a single marker was not sufficient to isolate
a pure population of stem cells. Ergo, EpSC purification was
the initial goal of the present study and was based on two
principles: (i) Since EpSCs are located in the epidermal
basal layer, the separation of this skin layer from the un-
derlying dermis would avoid contamination by a large
number of unwanted non-epithelial cells; and (ii) by seeding
the isolated cells at a clonal density in non-coated flasks,
EpSCs might be purified, as only those cells that have the
ability to clonally expand in suspension (a stem cell-specific
property) would survive [19], thereby substantially reducing
the survival of differentiated cell clusters.
The existence of undifferentiated cells that are capable of
surviving in suspension was first reported in 1986 [20].
Subsequently, these cells were designated as stem cells
because of their bipotent properties [21,22]. To date, dif-
ferent stem cell types have been isolated, such as mammary
stem/progenitor cells [23], corneal stem/progenitor cells
[24], and neural stem cells [25]. The use of non-coated
flasks was later employed to isolate spherical cell clusters
derived from human hair follicles [16]. Using embryonic
stem cell culture conditions, Yu et al. [16] succeeded in
forming cell clusters containing stem cells from skin folli-
cles. The isolated stem cells were not strictly EpSCs, as they
exhibited neurogenic properties. To our knowledge, there
are no reports of the harvesting of a homogenous population
of cells from mammalian epidermis that fulfil all the criteria
to merit classification as EpSCs. Therefore, the present
study is likely the first to describe the isolation, purification,
and immunophenotypical and functional characterization of
equine EpSCs.
Clinical applications of non-EpSCs for skin wound
healing have been described [26,27]. In this regard, the
improved healing capacity of persistent leg wounds in hu-
man diabetic patients in response to bone marrow-derived
mesenchymal stem cell (MSC) treatment was reported [28].
Moreover, it has been demonstrated that peripheral blood-
derived stem cells moderate the development of granulation
tissue and crust formation of naturally occurring wounds in
horses, which were unresponsive to more conservative
therapies [29]. However, in both studies, there was no evi-
dence of a decrease in scar tissue formation or an effect on
other functional parameters, such as elastin or collagen
production. In order to achieve restitutio ad integrum, it
might prove beneficial to use stem cells already committed
toward the keratinocyte fate. To our knowledge, there are no
reports of an experimentally controlled double-blinded
study of mammalian skin wound treatment with EpSCs.
Therefore, the second goal of this study was to compare
induced full-thickness skin wounds (positive control), skin
wounds treated with EpSCs plus platelet-rich plasma
(EpSC/PRP-treated), and skin wounds treated with PRP
alone. Since it has been previously indicated that PRP might
have synergistic effects on stem cell regeneration [30,31]
and that a fibrin-based matrix could support selective ad-
hesion, proliferation, and differentiation of keratinocyte pro-
genitors [32], we elected to use endogenous PRP as a carrier
for the EpSCs. Macroscopic and histological examinations
revealed significant differences between wound-healing pa-
rameters of EpSC/PRP-treated and PRP-treated samples.
Materials and Methods
Sampling, epidermal cell harvesting,
and epidermosphere formation
Samples were collected immediately after the sacrifice of
three horses in a government-certified slaughter house. Skin
tissue was obtained by excising 1 cm2 of full-thickness skin
in the neck region after clipping and surgical preparation
(scrubbing with iodide and disinfecting with 70% ethanol).
The samples did not show any macroscopic abnormali-
ties and were transported to the laboratory within 6 h in
phosphate-buffered saline (PBS) 1 · (without calcium and
magnesium) with 2% of penicillin-streptomycin-amfoter-
icine B (P/S/A; Sigma-Aldrich). The tissue samples were
treated with 0.25% trypsin-ethylenediamintetraaceticacid
(EDTA) (Gibco) solution at a temperature equal to or lower
than room temperature, for 12–18 h. Afterward, the epider-
mis was further mechanically detached from the dermis
(skin peeling). Subsequently, the epidermis was cut into
small pieces, and a second enzymatic dissociation step with
2% collagenase III (Worthington Biochemical Corporation)
at 37C for 60min was performed. The collagenase III was
inactivated by adding EpSC medium, consisting of Dul-
becco’s modified Eagle’s medium (DMEM)/F12 (Gibco),
20% fetal bovine serum (FBS; Gibco), 2% P/S/F, 20 ng/mL
human recombinant-basic fibroblast growth factor (FGF),
and 20 ng/mL epidermal growth factor (all from Sigma-
Aldrich). The suspension was then filtered (40mm; BD
Falcon) and washed with EpSC medium by centrifugation at
300g for 8min at room temperature. Approximately 5 · 103
cells/cm2 were planted per well of an ultralow attachment
six-well plate (Corning; Elscolab). The EpSC medium was
refreshed thrice a week by means of centrifugation of the
epidermospheres at 300g for 8min. After 1 week, the epi-
dermospheres were seeded on adhesive tissue culture dishes
in EpSC medium.
Epithelial cycle assay, colony-forming unit assays,
and population doubling time
After the first epidermosphere cycle, which developed from
skin tissue-derived cells on ultralow attachment plates (as de-
scribed earlier), all epidermospheres were collected at day 7
post-seeding and plated onto adhesive tissue culture dishes in
EpSCmedium.Onreaching80%confluency, the adherent cells
were trypsinized with 0.25% trypsin-EDTA and seeded at a
clonal density of 1 and 100 cells/cm2 on ultralow attachment
plates to initiate a second epidermosphere cycle and of 1 cell/
cm2 on adherent plates for 1 week for colony-forming unit
(CFU) assays for the three skin samples in triplicate. The ad-
herent CFUs were counted after fixation with 90% ethanol for
10min at - 20C. Crystal violet staining (Sigma-Aldrich) was
performed to visualize CFUs macroscopically, and the total
numberofCFUsper six-well platewas counted. In addition, the
second-cycle epidermospheres were counted and related to the
number of planted cells.
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Population doubling time (PDT) in days was calculated
from P0 to P10 as previously described [4], using the fol-
lowing formula: T/[log(Nf/Ni)/log2] with T the time in days,
Nf the final number of cells, and Ni the initial number of cells.
Flow cytometry
To characterize the epidermosphere-derived cells im-
munophenotypically, the expression of several stem cell
markers was evaluated by flow cytometry. Per series, 200,000
cells were used and labeled with the following primary an-
tibodies: mouse anti-human CD29-FITC IgG2a (Abcam;
clone B-D15, 1:10), rat anti-mouse CD44-FITC IgG2b (Ab-
cam; clone IM7, 1:20), rat anti-mouse CD49f IgG2a (Abcam;
clone GoH3, 1:10), mouse anti-dog CD90 IgM (VMRD;
clone DH24A, 1:100), mouse anti-human CD105-PE IgG1
(AbD Serotec; clone SN6, 1:50), mouse anti-horse major
histocompatibility complex (MHC) class I IgG2a (Wa-
shington State University; 1:50), mouse anti-horse MHC
class II IgG1 (Abd Serotec; 1:50), and rabbit polyclonal anti-
human Ki67 IgG (Abcam; 1:200). For Ki67, cells were fixed
with 4% paraformaldehyde for 10min and, subsequently,
permeabilized with 0.1% Triton X for 2min at room tem-
perature. Cells were incubated with the primary antibodies for
15min on ice in the dark and washed twice in washing buffer,
consisting of DMEM with 1% bovine serum albumin. For
CD49f, CD90, MHCs, and Ki67, secondary goat anti-rat-
FITC (Abcam, 1:100), goat anti-mouse-Cy5 (Abcam; 1:100),
rabbit anti-mouse-FITC (Abcam, 1:100), and goat anti-rabbit-
Cy5 (Abcam; 1:100) antibodies were used, respectively, to
identify positive cells after 15 minutes of incubation on ice in
the dark. Finally, all cells were washed thrice in washing
buffer, and at least 10,000 cells were evaluated using a
FACS. All analyses were based on (i) autofluorescence and
(ii) control cells incubated with isotype-specific IgGs, in or-
der to establish the background signal. All isotypes were
matched to the immunoglobulin subtype and used at the same
protein concentration as the corresponding antibodies.
Differentiation experiments
Differentiation of putative EpSCs toward two major cell
types present in the skin, namely adult epithelial cells (or
keratinocytes) and adipocytes, was induced using distinct
differentiation protocols. The first protocol consisted
of culturing 5 · 103 EpSC/cm2 in keratinocyte differentia-
tion medium, containing DMEM/F12 (Gibco), 20% FBS
(Gibco), 5 mg/mL insulin, 1 mg/mL hydrocortisone, and
0.1mM beta-mercaptoethanol (all from Sigma-Aldrich) for
10 days. Media were refreshed every 3–4 days, and immu-
nohistochemistry (IHC) was performed to evaluate the
expression of markers present in differentiated epithelial
cells (see next). Keratinocyte differentiation was repeated in
suspension cultures using the differentiation medium men-
tioned earlier for 10 days as well. The second protocol was
needed for adipogenic differentiation, and here, 4 · 104
cells/cm2 were planted in adipogenic inducing medium
(adapted from Spaas et al. [5]) consisting of DMEM (Gibco)
that was supplemented with 10 mM dexamethasone, 0.5mM
3-isobutyl-1-methylxanthine, 10mg/mL recombinant hu-
man-insulin, 0.5mM indomethacin, and 15% rabbit serum
(all from Sigma-Aldrich). Differentiation was evaluated after
3 days of cultivation using Oil Red O (Sigma-Aldrich)
staining. As a control for the bilineage differentiation, puta-
tive EpSCs were cultivated for the same time in EpSC me-
dium, at the same density, and in identical culture vessels.
IHC on cells
Adhesive cell cultures were stained in their culture dishes,
whereas epidermospheres cultured in suspension were see-
ded onto normal tissue culture plates for 1 h to enable ad-
herence, or cytospins were prepared. After that, cells were
fixed for 10min with 4% paraformaldehyde and permeabi-
lized for 2min with 0.1% Triton X, both of which were at
room temperature. Cells were then incubated with hydrogen
peroxide for 5min followed by washing with PBS before
incubation for 2 h at room temperature with the following
primary mouse IgG1 monoclonal antibodies: anti-human
cytokeratin (CK)14 (Abcam; clone LL002, 1:50), anti-
human CK18 (Abcam; clone C-04, 1:30), anti-human Pan CK
(Dako; clone, AE1/AE3, 1:50), and anti-porcine vimentin
(Abcam; clone V9, 1:100); the mouse anti-human smooth
muscle actin (SMA) IgG2a Ab (Dako; clone 1A4, 1:200); and
the following rabbit antibodies: anti-human Wide CK (Ab-
cam; 1:50), anti-human Ki67 (Abcam; 1:200), anti-human
casein kinase 2b (Abcam; clone EP1995Y, 1:50), and anti-
human p63 (Abcam; 1:50). After washing with PBS, sec-
ondary ready-to-use goat anti-mouse and anti-rabbit peroxi-
dase (PO)-linked antibodies (Dako) were added and
incubated for 30min at room temperature. Finally, 3,3¢-
diaminobenzidine (DAB) was added for 2–10min, and a
counter staining with hematoxylin was performed to visualize
the surrounding cells. As controls, identical staining was
performed on undifferentiated EpSCs, and background
staining was assessed by using the proper isotype-specific
IgGs. All isotypes were matched to the immunoglobulin
subtype and used at the same protein concentration as the
corresponding antibodies.
In vivo study
After local anesthesia and surgical preparation, six full-
thickness skin wounds of *4 cm2 were induced in a 5-year-
old gelded horse dorsally from the musculus gluteus medius
(three on the left side and three on the right side). Three
randomly assigned wounds received allogenic putative
EpSCs (derived from a slaughter horse skin sample) in
combination with autologous PRP (EpSC/PRP-treatment) as
a carrier, and the three remaining wounds were treated
identically, but without putative EpSCs (PRP injection only).
The EpSC/PRP-treatment consisted of two approaches: First,
an intradermal injection (0.5mL in each of the four wound
edges) of 1mL of DMEM containing 8· 106 freshly prepared
putative EpSCs at passage 3 in combination with 1mL of
PRP (prepared as previously described [30,33]) was admin-
istered. Immediately afterward, a topical application of
0.5mL DMEM containing 4· 106 putative EpSCs and
0.5mL of PRP was performed. The topical application was
repeated after absorption of the liquid, which was after 24 h.
The PRP treatment was performed in exactly the same
manner; however, the DMEM did not contain EpSCs in this
group. Wounds were not sutured, but covered with an adhe-
sive, non-absorbable plastic in which micropores were made
in order to enable oxygen access. The horse was bound in his
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stable for 24 h in order to prevent rolling, and photographs
were taken every 3–4 days. Wounds were measured and
surfaces were calculated immediately before and 30 days
after treatment by a veterinarian under double-blinded con-
ditions. The experimental protocol was approved by the
ethics committee (EC_2012_002) of Global Stem cell
Technology (LA1700607).
Histology of tissue sections
On day 30, an 8mm punch biopsy was taken from the
center of the wound (covering the whole wound area) for
tissue sampling. The specimens were fixed in neutral-
buffered 10% formalin, embedded in paraffin, sectioned at
4 mm thickness, and stained with Hematoxylin and Eosin,
Van Gieson (VG), and Elastin stains according to standard
protocols.
All samples were blindly analyzed by an ECVP-certified
pathologist (S.M.) using a modified scoring system, adapted
from Abramov et al. [34] and Babaeijandaghi et al. [35]
(Table 1). Briefly, the epidermis was scored for thickness
(0–3), crust formation (0–1), dermo-epidermal separation
(0–2), and completeness of re-epithelization (0–3). Sections
of positive control skin originating from the same horse
Table 1. Different Skin-Healing Parameters that were Scored in the Present Study
Parameter Score
Epidermis Acanthosis 0 = severe (> 15 layers) or moderate irregular,
1 =moderate regular (10–15 layers),
2 =mild (5–10 layers),
3 = none
Crust 0 = present
1 = absent
Dermo-epidermal separation 0 =multifocal to diffuse
1 = focal
2 = none
Re-epithelization 0 = none
1 = scant
2 = complete but immature/thin
3 = complete and mature
Dermis Edema 0 = severe
1 =moderate
2 =mild
3 = none
Stroma Collagen amount (VG stain)
+ thickness dermis
0 = severely raised
1 =moderately raised
2 =mildly raised
3 = normal
Collagen morphology
(VG stain)
0 =mostly amorphous
1 =mostly thin wavy
2 =mostly thick wavy
Elastin amount (eVG stain) 0 = not/scarce in repair tissue
1 = few in repair(ed) tissue
2 = normal distribution and amount
Maturation fibroblasts 0 = none
1 =mild
2 =moderate
3 = full
Granulation tissue Amount + thickness measured 0 = abundant
1 =moderate
2 =mild
3 = none
Neovascularization Number of capillaries per
200 · field, (vWF IHC)
0 = abundant (25–35 per 200 · )
1 =moderate (15–25 per 200 · )
2 =mild (up to 15 vessels per 200 · )
3 = none
Acute inflammation 0 = abundant
1 =moderate
2 =mild
3 = none
Chronic inflammation 0 = abundant
1 =moderate
2 =mild
3 = none
Adapted from Abramov et al. [34] and Babaeijandaghi et al. [35].
VG, Van Gieson; vWF, Von Willebrand Factor; IHC, immunohistochemistry.
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were made from the samples at the time of wound induction
(establishing a maximal score). The dermis was evaluated
using six main parameters: (i) edema (0–3); (ii) amount and
morphology of the stroma (thickness measured and scored
0–3, amount of collagen, and the morphology of collagen
fibers (thin/immature, intermediate, or thick/mature) using
VG stain and scored 0–2, amount of elastin using elastica
Van Gieson stain and scored 0–1); (iii) thickness and mor-
phology of the granulation tissue (thickness measured and
scored 0–3, maturation of fibroblasts scored 0–3); (iv)
neovascularization (scored 0–3 and average number of
capillaries counted per 200 · magnification field) on im-
munohistochemical stain for von Willebrand factor (vWF);
(v) acute inflammation/neutrophilic infiltrate (0–3); and (vi)
chronic inflammation/lymphoplasmacytic infiltrate (0–3).
Again, positive control sample values set a maximal score.
The average of three fields was used to evaluate different
histopathological parameters, and all measurements were
performed with a computer-based program (LAS V4.1;
Leica Microsystems).
IHC on tissue sections
In order to localize epithelial cells within the epidermis,
skin glands, and hair follicles, Pan CK and Wide CK were
used. Casein Kinase 2b and Ki67 indicated where prolifer-
ating [36] epithelial [37] cells were located within the
sample. To examine the role of EpSCs in elastin production
and neovascularization, tissue sections were stained with
mouse anti-bovine elastin IgG1 (Leica; clone BA-4, 1:100)
and rabbit anti-human vWF (Dako; 1:6,400), respectively.
Furthermore, the expression of the mesenchymal marker
vimentin [38] and the myogenic marker SMA [39] was as-
sessed. Immunolabeling was achieved with a high-sensitive
horseradish PO mouse or rabbit diaminobenzidine kit with
blocking of endogenous PO (Envision DAB + kit; Dako) in
an autoimmunostainer (Cytomation S/N S38-7410-01;
Dako). A commercially available antibody diluent (Dako)
with background-reducing components was used to block
hydrophobic interactions. All skin samples (including pos-
itive and negative controls) were submitted to the same
immunohistochemical staining procedure.
Statistical analysis
Data were analyzed using the two-tailed Student’s t-test
for group comparisons of normally distributed variables.
Values were given as means– standard deviation (bars).
P-values were calculated using an Excel spread sheet (2007;
Microsoft Corp.), and P < 0.05 was considered a probabi-
listically significant difference between the compared
groups of samples.
Results
Epidermis-derived cells are classified as EpSCs
Epidermis-derived cells are capable of epidermosphere for-
mation, proliferate clonally in suspension, and exhibit similar
expansion capacities on substrate adhesion as well as in sus-
pension. After performing the skin peeling protocol, the
epidermis could be removed without the inclusion of
hair follicles or other dermal structures (Supplementary
Fig. S1; Supplementary Data are available online at www
.liebertpub.com/scd). Epidermis-derived EpSCs were iso-
lated and purified by seeding at a critically low density
(5 · 103 EpSCs/cm2), followed by epidermosphere forma-
tion. The first small epidermospheres (consisting of an
average of two cells per sphere) could be observed in all
cultures as early as 1 day post seeding (Fig. 1A, C). When
attempting epidermosphere formation on normal tissue
culture plates, EpSCs attached within 3 h (Fig. 1D), clearly
dispersed after 1 day (Fig. 1E), and reached confluency
at *day 5 (Fig. 1F).
Moreover, after dissociating the epidermospheres into
single cells and seeding 100 EpSCs/cm2 (1,000 EpSCs/
six-well), approximately the same amount of spheres were
formed after 1 day and the average number of spheres
(1,203 vs. 1,240 vs. 1,157) remained relatively constant
during the 1 week cultivation period (Fig. 2A), indicating
that most epidermosphere-derived EpSCs maintained their
phenotype and were capable of giving rise to subsequent
generations of spheres. Indeed, since sphere formation was
initiated within 1 day and it takes at least 24 h for EpSCs to
divide (data not shown), we may conclude that all the
EpSCs were at the origin of the newly formed epidermo-
spheres. In addition, the number of EpSCs significantly in-
creased at day 4 (P < 0.001) and 7 (P < 0.0001) from the first
day of culture, indicating that all EpSCs were capable of
clonal expansion in suspension (Fig. 2B).
To compare the self-renewal capacity and clonogenic
expansion of EpSCs in adherent cultures as well as in sus-
pension, a critically low number of cells (1/cm2) was seeded
at a clonal density on large surfaces and cultured for 1 week.
Although the CFU assay for the first skin sample demon-
strated significantly (P < 0.02) more CFUs in adhesion than
epidermospheres in suspension, the second skin sample
exhibited the opposite trend (P < 0.01). Summing the three
samples together, an average of one CFU (one epidermo-
sphere per cm2) or 11 CFUs (spheres) per six-well plate
were formed within the first week (Fig. 2C). This implied
that every epidermosphere-derived cell had the capacity to
clonally multiply both in adhesion as well as in suspension.
Another indication of the self-renewal capacity of the
EpSCs was their PDT (in days) over multiple passages
(from P0 up to P10). The EpSCs from all three skin samples
divided rapidly as shown by a positive PDT varying be-
tween 0.78 and 1.16 for all passages tested.
Marker expression of epidermis-derived EpSCs. The epi-
dermis-derived EpSCs were immunophenotypically char-
acterized by flow cytometry, and approximately all cells
were positive for the stem cell surface markers CD29,
CD44, CD49f, and CD90 (Fig. 2D). Moreover, EpSCs were
positive for the proliferation marker Ki67. Cross-reactivity
of all the markers was evaluated with the appropriate pos-
itive controls using flow cytometry or immunofluorescence
(data not shown). No fluorescence signal was obtained with
the MSC marker CD105 (Fig. 2C), with MHC II (Supple-
mentary Fig. S2), or with the appropriate isotype controls.
Moreover, a low expression of MHC I (Supplementary Fig.
S2) was observed. Peripheral blood mononuclear cells were
used as positive controls to confirm MHC cross-reactivity
(Supplementary Fig. S2).
Equine EpSCs can differentiate into different keratinocyte
subtypes and adipocytes. After culturing EpSCs in the
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keratinocyte differentiation medium for 10 days, two dif-
ferent adult cell types appeared in the culture. Stellate-
shaped cells (form several cobblestone-like cells after
differentiation for 15 days, Supplementary Fig. S3) became
evident that were positive for specific keratinocyte [40] and
follicular cell markers (cfr. positive control data), including
CK14, CK18, Pan CK, and Wide CK in adhesion as well as
in suspension (Fig. 3; Supplementary Figs. S4 and S5).
Within the differentiated cell culture, cylindrical-shaped
cells arose that were positive for vimentin (Fig. 3G) and
SMA (Fig. 3H). EpSCs and the differentiated cultures were
negative for relevant isotype controls. Undifferentiated
EpSCs stained negative in adhesion (Fig. 3A, C, E) as well
as in suspension (Supplementary Fig. S4) for CK18, Pan
CK, and Wide CK. Moreover, undifferentiated EpSCs ex-
pressed low cytoplasmic levels of CK14 (Supplementary
Fig. S5B, C), but were clearly positive for the proliferation
marker Ki67 [36] (Supplementary Fig. S6) and the epithelial
marker Casein Kinase 2b [37] (Supplementary Fig. S6),
both of which sharply decreased on differentiation (Sup-
plementary Fig. S6). Finally, most of the EpSCs as well as
several of their more differentiated progeny were positive
(nuclear and weaker cytoplasmic signal) for the epithelial
stem cell marker p63 [41,42] in adhesion as well as in
suspension (Supplementary Fig. S7). Cross-reactivity of all
the markers was evaluated with the appropriate positive
controls via dot blots (data not shown) and/or via IHC (data
not shown).
Interestingly, within 3 days of culturing in adipogenic-
inducing medium, EpSCs changed from a spindle-shaped to
a round morphology that was concomitant with the pro-
duction of small intracellular granules, microscopically de-
tected in all cultures (Fig. 3K). Subsequently, Oil Red O
staining confirmed the presence of lipid droplets in these
cells (Fig. 3L), indicating that EpSCs are capable of dif-
ferentiating into adipocytes. Non-differentiated control
EpSCs maintained their spindle-shaped morphology (Fig.
3I) in monolayers after cultivation in EpSC medium for 3
days and stained negatively for lipid droplets (Fig. 3J).
EpSC/PRP-treated skin wounds display a higher
regenerative profile than PRP-treated wounds
EpSC/PRP-treated wounds display macroscopic-enhanced
healing capacities. Wounds were measured at the day of
induction and again 30 days later (Fig. 4). Despite the ex-
amining veterinarian perceiving no difference, surface cal-
culations were performed by dividing the remaining repair
tissue in mm2 by the initial wound area in mm2 · 100. This
revealed an average of 79% (100% - surface calculation) of
FIG. 1. The epithelial-like stem/progenitor cell (EpSC) cycle. After epidermosphere formation on ultralow attachment
plates (A, C), EpSCs were cultured on tissue culture dishes, and the attachment (B) and proliferation process is shown at 3 h
(D), 1 day (E), and 5 days (F) after adherence. Scale bars represent 50mm.
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the wound surface that was filled (granulation and epithe-
lialization) in the EpSC/PRP-treated group, which was
significantly different (P< 0.01) from 72% for the PRP-
treated group (Fig. 4).
EpSC/PRP-treated wounds display microscopic-enhanced
healing capacities. In all skin samples, a normal to mild
acanthotic, mature epidermis with crust formation (Fig. 5B,
C, E, F) was constituted at day 30. Image-based length
measurements revealed a considerably higher amount of
collagen and a significantly (P< 0.02) thicker dermis in the
PRP-treated samples (7.4 – 0.6mm, Fig. 5B, E) compared
with the EpSC/PRP-treated (5.6 – 0.9mm, Fig. 5C, F) and
positive control samples (5.7 – 0.4mm, Fig. 6A, D). PRP-
treated wounds also contained a considerably higher amount
of granulation tissue (6.4– 0.4mm), compared with the
EpSC/PRP-treated wounds (5.1 – 0.8mm). In all skin sam-
ples, a mild acute inflammation (polymorphonuclear cells)
was present and in five out of six cases, a mild (Fig. 5G) to
moderate (Fig. 5H) chronic inflammation (lymphocytes and
plasma cells) was observed that was mainly restricted to
perivascular regions, yet in some instances extended to the
interstitial regions. In one sample from the PRP-treated
group, an abundant number of inflammatory cells could be
noticed in a localized area (Fig. 5I). There were no signifi-
cant differences in histopathology scoring with regard to the
degree of edema and the morphology of the dermal stroma
or granulation tissue.
When evaluating Casein Kinase 2b and Ki67—which
were present in the EpSCs and decreased during differen-
tiation—a few cells in the epidermal basal cell layer and the
hair follicle stained positively in the nucleus (Fig. 6A, D).
Within the newly formed dermis, the EpSC/PRP-treated
wounds revealed areas with many positive cells for Casein
Kinase 2b (Fig. 6C) and Ki67 (Fig. 6F), whereas PRP-
treated wounds contained, at most, a single positive cell per
400 · magnification field (Fig. 6B, E). When evaluating
FIG. 2. Epidermosphere formation assay. After planting 100 EpSCs/cm2 (1,000 EpSCs/six-well), the average number of
spheres (white histograms) of the three skin samples remained approximately the same at day 1, 4, and 7 (Y-axis) after
seeding (A); whereas the average number of EpSCs (white histograms) of the three skin samples increased over time (Y-
axis) (B). Sphere formation and colony-forming unit (CFU) assays (C) after planting 1 EpSC/cm2 (10 EpSCs/well of a six-
well plate) revealed an average (Av) of 11 spheres (white histogram) and 11 CFUs (black histogram) after 1 week of
cultivation. Immunophenotypic characterization of EpSCs (D). Flow cytometry confirmed positivity for CD29, CD44,
CD49f, CD90, and Ki67. The mesenchymal stem cell marker CD105 was negative on the EpSCs. Histograms show relative
numbers of cells versus mean fluorescence intensity with the isotype control staining (light gray) and marker antibody
staining (dark gray). In all figures, the data represent the mean percentage of three experiments ( – standard deviations).
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epithelial markers (Wide CK and Pan CK) in the intact skin
sections, epidermal cells, adnexal glands, and follicular
epithelial cells stained strongly positive (Fig. 6G). When
evaluating these markers in follicle-like structures in the
dermis, these structures seemed more developed in the
EpSC/PRP-treated group (Fig. 6I) than in the PRP-treated
group (Fig. 6H). In both treatment groups, the newly formed
epidermis stained diffusely positive for CK markers (data
not shown). Neovascularization was evaluated by means of
vWF staining and a considerably, yet non-significant
(P = 0.26), higher average of dermal blood vessels (31– 4)
per 200· magnification field was noticed in EpSC/PRP-
treated wounds (Fig. 6L) compared with the PRP-treated
wounds (23 – 4) (Fig. 6K).
Histochemical elastin staining revealed no considerable
differences between the EpSC/PRP- and PRP-treated skin
samples (data not shown), whereas IHC revealed a remark-
ably higher elastin production around follicle-like structures
in the dermis of EpSC/PRP-treated wounds (Fig. 6O), re-
sembling intact skin structures (Fig. 6M). On the contrary,
there was only scarce elastin staining in the PRP-treated
group (Fig. 6N). SMA cytoplasmic immunolabeling revealed
a thin line of positive cells surrounding hair follicles and
sweat glands (Fig. 6P). Moreover, the arrector pili muscles
and vascular tunica media stained strongly positive for SMA
(Fig. 6P), as well as a subset of follicular cells (mainly in
lower follicular outer root sheath and higher inner root sheath
layer). Both PRP- and EpSC/PRP-treated wounds contained
dense areas of SMA (Fig. 6Q)-positive cells in the dermis.
However, EpSC/PRP-treated wounds also contained large
zones with minimal SMA staining, a feature that was absent
in PRP-treated wounds. In addition, a thin layer of SMA-
positive cells encircling dermal follicle-like structures was
present in EpSC/PRP-treated wounds (Fig. 6R), a pattern very
similar to SMA staining in intact skin.
Discussion
Although the isolation of sphere-forming progenitor cells
was described in 1986 [20], the main problem using sus-
pension cultures for stem cell isolation was potential con-
tamination with other cell types which are capable of
surviving this selection process by insinuating themselves to
surviving stem cells in the clusters. It should be noted that
the present study describes a peeling technique using me-
chanical and enzymatic digestions to separate epidermal
cells from their surrounding tissue as well as a method to
enrich for EpSCs by seeding at a low density, followed by
epidermosphere formation. Finally, the isolated EpSCs were
characterized and clinically evaluated.
Briefly, the equine EpSCs were immunophenotypically
characterized by using the universal stem cell markers
CD29, CD44, CD49f, and CD90. The nuclear marker Ki67,
which is expressed during the (G)1, synthesis (S), and G2/
mitosis (M) phases of the cell cycle [36], was used to give
an indication of the self-renewal capacity of the EpSCs. The
markers CK18, CD105, and p63 were used to make a clear
distinction from equine MSCs. MSCs are positive for both
CK18 (data not shown) and CD105 [5], which is not the case
for EpSCs; whereas p63 is absent in MSCs [43,44] and was
present in the nucleus and cytoplasm of EpSCs. These re-
sults are in agreement with previous reports examining p63
FIG. 3. Differentiation of EpSCs into keratinocytes and adipocytes. Immunohistochemistry on the EpSCs confirmed that
cytokeratin (CK)markers, CK18 (A), Pan CK (C), andWide CK (E) stained negative. Differentiated keratinocytes were positive
for CK18 (B), Pan CK (D), andWide CK (F). The EpSCs also had the capacity to turn into cylindrical cells that were positive for
vimentin (G) and smoothmuscle actin (SMA) (H). To evaluate adipogenesis, EpSCs were cultured in normal expansionmedium
as a control (I, J) and adipogenic differentiation medium (K,L). Samples were analyzed by light microscopy (I,K) and after Oil
Red O stainings (J, L). Scale bars represent 50mm. Color images available online at www.liebertpub.com/scd
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expression in corneal stem cells [41,42] and circulating
keratinocyte progenitor cells [32]. Moreover, the EpSCs in
the present study were positive for Casein Kinase 2b, which
is reputed to inhibit the development of the mesenchymal
morphology and phenotype [37,45], and plays an important
role in the functional regulation of epithelial cells [46–48].
To date, different markers for stem cell localization in
mammalian skin have been identified; however, EpSC-
specific markers are lacking due to lack of tissue specificity.
For instance, stem cell factor has been reported as an indi-
cator for skin stem cells, despite its expression by mature
melanocytes [49]. Other markers, such as CK19 [12] and
b-catenin, are expressed not only in skin stem cells [50],
but also by differentiated epidermal cells [11]; whereas
b-catenin is also present in lymphocytes [51]. In this study,
Casein Kinase 2b and Ki67 were used to quantify the
number of proliferating [36] epithelial cells [37]. These
markers were present in EpSCs in vitro and became further
up-regulated in the EpSC/PRP-treated group in vivo. Blan-
pain and Fuchs found that stem cells in the epidermis divide
asymmetrically to enhance the EpSC pool as well as to
provide a more differentiated progeny pool [52], helping
explain the increased incidence of EpSCs 30 days after
EpSC/PRP treatment. Moreover, in the intact skin samples,
both markers only coincided in areas where EpSCs were
located: the epidermal basal cell layer, transition of dermal
papilla, and bulge of the hair follicle. Indeed, the presence of
stem cells has been previously reported in these areas [8,9].
Sphere formation is a frequently used method to enrich
for stem/progenitor cells by culturing enzymatically di-
gested cells on ultralow attachment plates to prevent adhe-
sion [53]. These spheres commonly consist of a mixture of
stem/progenitor cells, their progeny, and non-stem progen-
itor cells, as previously described by Stingl in 2009 [54]. In
contrast to the study of Toma where a crude dermal cell
suspension was cultured and sphere formation was obtained
[14], our study describes the cultivation of epidermis-
derived cells at a clonal density under ultralow attachment
conditions. All the epidermosphere-derived cells had the
capacity to self-renew in a clonal manner with, or without,
the necessity for a surface to attach on. Moreover, the
number of planted cells (1 or 100 per cm2) corresponded
with the average number of CFUs or epidermospheres (1 or
100 per cm2) and the number of EpSCs per epidermosphere
FIG. 4. Macroscopic wound evaluation. Macroscopic images of the wound site at different time points (d = day) after
platelet-rich-plasma (PRP) treatment with (B, D, F) and without (A, C, E) skin-derived EpSCs. At each time point, the left
picture represents wounds (A–C) at the left side of the horse and wounds (D–F) at the right side. The table represents the
percentage of wound filling, calculated after measuring the areas before treatment (after induction at d0) and 30 days later
(d30). In the EpSC/PRP-treated wounds, a significantly larger area was filled at d30.
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significantly increased during the cultivation period, indi-
cating that the sphere-forming efficiency of these EpSCs
approached 100%. By contrast, Dontu reported sphere for-
mation in only 0.4% of planted mammary cells (4 per 1,000)
[53]. This would also imply that the epidermospheres are
100% homogenous.
In addition, a successful bilineage differentiation was
achieved toward two major skin cell types: keratinocytes
within 10 days and adipocytes within 3 days. EpSC differ-
entiation was confirmed in adhered cells as well as in sus-
pension by CK14, CK18, Pan CK, and Wide CK expression.
Since it has been previously reported that human embryonic
stem cells strongly up-regulate CK18 expression during
epithelial differentiation [55] and our positive control sam-
ples show the presence of CK18 in sweat gland epithelial
cells (data not shown), up-regulation of this marker can be
considered a reliable indication for differentiation toward
epithelial lineages. Moreover, the low level of CK14
expression in the EpSCs indicated that these cells were early
enough in differentiation, similar to the stage II cells during
keratinocyte differentiation of human embryonic stem cells
[56]. The increase in CK14 expression we observed, on the
other hand, might correspond to the stage III cells detected
in the study mentioned earlier, which represented more
differentiated keratinocytes.
Furthermore, after EpSC differentiation, a cell population
arose that stained positive for vimentin and SMA. In this
regard, it has been reported that human basaloid keratino-
cytes [57] and equine lamellar cells [58] were positive for
vimentin. In addition, up-regulation of SMA has been re-
ported in human epidermal keratinocytes under certain
conditions (hydrogen peroxide treatment) as well [59]. In
our hands, the intact skin samples that were used as positive
controls also contained vimentin and SMA positive epider-
mal and follicular cells (data not shown). Whether the
positive cells in our keratinocyte differentiation culture were
FIG. 5. Hematoxylin-eosin
(A–C, G–I) and Van Gieson
(D–F) stainings on the intact
skin samples (A, D), PRP-
treated group (B, E), and
EpSC/PRP-treated (C, F)
group. Chronic inflammation
was evaluated by mild (G),
moderate (H), or abundant (I)
lymphocyte and plasma cell
infiltration. Scale bars rep-
resent 1mm (A–C), 200mm
(D–F), and 100mm (G–I).
Color images available online
at www.liebertpub.com/scd
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a keratinocyte subpopulation or displayed a myofibroblast
phenotype remains to be determined.
In the present study, most of the EpSCs and several dif-
ferentiated cells expressed p63, which is a transcription
factor that is essential for epithelial development and pro-
liferation as well as for epidermal differentiation and strat-
ification [60,61]. It has been reported that more than 60% of
isolated human corneal and limbal epithelial cells were
positive for this marker [62]. Unlike previous findings in
horse skin [63], it should be mentioned that in this study,
using a rabbit polyclonal antibody directed to a mix of p63
isoforms, the expression of p63 was not restricted to the
nucleus. Immunoblotting analyses later confirmed cross-
reactivity of the antibody with our equine EpSCs. Dilution
optimization, as well as isotype and positive controls further
validated these results, revealing cytoplasmic localization
(data not shown). By contrast, Carter et al. described strictly
nuclear signals using mouse monoclonal antibodies directed
to the delta N region of the peptide in equine skin samples
[63]. It is likely that the noted discrepancies in cellular lo-
calization associated with the different antibodies arise from
the differences in epitope specificity. In several studies
[32,64], other markers for adult keratinocytes were used,
such as CK5 and E-Cadherin; however, we were unable to
FIG. 6. Immunohistochem-
istry staining on the intact
skin samples [left column:
(A, D, G, J, M, P)], PRP-
treated group [middle col-
umn: (B, E, H, K, N, Q)]
and EpSC/PRP-treated group
[right column: (C, F, I, L, O,
R)]. Casein Kinase 2b (A–C)
and Ki67 (D–F) indicate the
location of proliferating epi-
thelial cells, whereas Pan CK
and Wide CK (G–I) show
the location of adult kerati-
nocytes. Neovascularization
is visualized after staining
with Von Willebrand Factor
(J–L). Elastin (M–O) pro-
duction and SMA-positive
cells (P–R) were also evalu-
ated. Besides the scale bars
of ‘‘(A, J, K, L)’’ that are
100mm, all bars represent
20mm. The arrows indicate
positive stainings. Color ima-
ges available online at www
.liebertpub.com/scd
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evaluate the expression of these markers in or on our equine
EpSCs or their differentiated progeny, due to a lack of cross-
reactivity of several commercially available antibodies tes-
ted (data not shown). In this regard, it has been reported that
only about 4% of human antibodies reacts with the equiv-
alent equine epitopes [65]. Finding suitable antibodies is,
therefore, a challenge in equine studies.
Adipogenic differentiation is usually described after 21
days for MSCs [5]; however, recently, adipogenesis of
mammary stem/progenitor cells has been reported as soon as
5 days [66] and even 3 days in the present study. If MSCs
would be stained after 3 days of adipogenic differentiation
under the same circumstances, adipocytes might also be
detected. In that case, the percentage of stained cells should
provide more insights into this matter. It should be men-
tioned that adipogenic differentiation of cells derived from
the epidermal basal cell layer was somehow unexpected.
However, adipogenic differentiation capacities of (human
amnion and chicken oviduct) epithelial cells have been
previously reported by other groups as well [67,68]. Further
study would be essential to demonstrate the potency of these
cells and their capacity for complete tissue reconstitution in
vitro or in vivo.
For a second intention of wound healing, skin grafts from
other parts of the body are the treatment of choice [69].
However, accessory skin loss, infection, and difficult at-
tachment to the underlying and surrounding tissues are
major complications, reducing the chance of success of skin
transplantation in horses [70–73]. Since skin allograft re-
jection is a well-known risk in humans [74] as well as horses
[75], skin tissue from other horses is mainly being used as a
biologic dressing [76]. With regard to regenerative medi-
cine, phase II clinical trials have been reported using allo-
genic MSCs to treat graft-versus-host disease in humans
[77,78]. In the present study, the EpSCs were low in MHC I
and negative for MHC II, reflecting low immunogenicity. In
this regard, it has been reported that allogenic MSCs, which
were also negative for MHC II, did not induce an immune
response after intravenous and intradermal injections in
horses [79,80]. Whether or not other allogenic non-EpSC
cell types would have the ability to cause similar clinical
improvements remains to be proved.
We observed statistically significant (P< 0.01) improve-
ments in macroscopic wound filling after EpSC/PRP treat-
ment. Other studies have also observed enhancement in
wound healing with other stem cell classes using visual as-
sessment [28,29]. In order to assess whether or not restitutio
ad integrum (full restitution of tissue integrity and function-
ality) was achieved, a double-blinded histological study was
performed in this study. Via such an approach, a significantly
thinner granulation tissue and a more normalized diameter
were apparent in all EpSC/PRP-treated wounds when com-
pared with PRP-treated wounds. Both the more moderate
dermis and granulation tissue formation in the EpSC/PRP-
treated wounds indicate the formation of a tissue that more
closely resembles the original intact skin (positive controls).
Considerably more mature follicle-like structures could also
be noticed in the EpSC/PRP-treated wounds, further dem-
onstrating a more advanced regenerative state and tissue in-
tegrity. The follicles mentioned earlier were commonly
surrounded by SMA-positive cells in all treated wounds, a
feature that was absent in PRP-treated wounds.
In addition, the EpSC/PRP-treated wounds contained sig-
nificantly more elastin fibers and closely resembled positive
controls at 30 days post injection, whereas the PRP-treated
wounds revealed only a minor elastin-like substance at the
same point in time. In this regard, it has been recently reported
that the amount of elastin correlates with scarless healing [81].
Indeed, elastin provides skin resistance, matrix synthesis, and
supports a range of cell activities, including cell migration and
proliferation [81]. Therefore, the presence and organization of
elastin is a desirable trait in wound-healing evaluation. Neo-
vascularizationwas evaluated bymeans of vWF staining, and a
considerably higher average amount of blood vessels was no-
ticed in the EpSC/PRP-treated group (31– 4 vs. 23– 4 per
200· ). Indeed, stem cell therapy has been earlier associated
with an increase in vascularization [26,27,82], and there is the
possibility that an enhanced nutrition supply to the wound site
also has beneficial effects on wound healing. To date, different
angiogenic regulating factors have been identified: interleukin-
8 [82], fibroblast growth factors [83], vascular endothelial
growth factors (VEGFs) [84], angiopoietins [85], platelet-
derived growth factors (PDGFs) [83], and matrix metallopro-
teinases [86]. In this regard, it has been described that adult
stem cells (MSCs) promote angiogenesis through cytokine and
protease expression [87]. In addition, it has been hypothesized
that MSCs can function as pericytes, surrounding the blood
vessels [88,89].Although no such data are available for EpSCs,
one might postulate that these cells exert a trophic influence on
blood vessel formation. Alternatively, platelets in the PRP-
treated wounds could secrete different growth factors, such as
PDGF and VEGF, which also have an angiogenic effect [90].
Nevertheless, it has been reported that platelet degranulation
induces pro-angiogenic signaling in epithelial cancer cell lines
[91]. This might explain how the combination of EpSCs and
PRP increased the vascularization in comparison to PRP only
Conclusion
In conclusion, this study is the first that reports the isolation
and purification of equine EpSCs. Moreover, we describe an
immunophenotypical and functional characterization of the
isolated cells. In addition, a double-blinded clinical study
revealed significant macroscopic as well as microscopic im-
provements in different wound-healing parameters after
EpSC/PRP treatment.
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